In the transition to a renewable energy future, we must invest in a new transmission infrastructure – some crossing state borders – that connects intermittent power, traditional power and users, write Center for Energy Studies experts.
Kenneth B. Medlock III, Olivera Jankovska, Julie A. CohnFebruary 22, 2021
Through both engineered and natural carbon sinks, the U.S. is well-positioned to embark on a comprehensive national strategy aimed at decarbonization. This brief outlines a range of climate solutions and policy recommendations to address the challenges of greenhouse gas mitigation.
Kenneth B. Medlock III, Keily MillerJanuary 22, 2021
Experts from the Center for Energy Studies offer nine climate policy recommendations for the Biden administration and argue that a bipartisan legislative push could accelerate a move toward significant action on climate change.
Jim Krane, Kenneth B. Medlock III, Mark Finley, Michael D. MaherJanuary 20, 2021
The authors assert that the time is ripe for the United States and Europe to take the lead on shepherding a systems-level change in the recycling market, strengthened by government regulation and legislation. They examine the economic, social, and environmental impacts of mismanaged waste and argue that the Covid-19 pandemic could serve as a catalyst for action toward a global, circular economy.
The authors outline a cure for a component of the U.S.-China Phase 1 Trade Agreement that requires China to purchase $50 billion of energy products in the next two years.
Steven R. Miles, Kenneth B. Medlock IIIApril 1, 2020
The high-growth, high-tech sector appears poised to dramatically grow. U.S. policy to support this sector could enhance and hasten its rise, or could destroy a new American dream.
To harness the power of the market for ideas, the federal government must fund the U.S. patent office to 21st century levels and enhance the rights of patent owners.
Ambassador Edward P. Djerejian, director of the Baker Institute, makes the case for a comprehensive North American strategy in which the U.S., Mexico and Canada act in concert to become the global superpower of the 21st century.
High cancer drug prices significantly contribute to health care costs in the United States, with the average annual price of new cancer drugs increasing from less than $10,000 before 2000 to $145,000 in 2015. Baker Institute fellows Hagop M. Kantarjian and Vivian Ho highlight this issue and propose possible solutions.